{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:47:27Z","timestamp":1791276447153,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Intravenous pamidronate is the most widely used treatment for moderate to severe osteogenesis imperfecta (OI). Currently, there is no medical treatment for patients with mild OI. We conducted a single-center randomized double-blind placebo-controlled trial to examine the efficacy and safety of oral risedronate in the treatment of pediatric patients with mild OI. A total of 26 children and adolescents (age, 6.1\u201317.7 yr; 11 girls) with OI type I were randomized to either placebo (N = 13) or risedronate (N = 13) for 2 yr. Risedronate doses were 15 mg once per week in patients weighing &amp;lt;40 kg and 30 mg once per week in patients weighing &amp;gt;40 kg. After 2 yr of treatment, risedronate decreased serum levels of the bone resorption marker collagen type I N-telopeptide by 35% compared with a 6% reduction with placebo (p = 0.003). Risedronate increased lumbar spine areal BMD Z-scores by 0.65, whereas patients receiving placebo experienced a decrease of 0.15 (p = 0.002). In contrast, no significant treatment differences in bone mass and density were found at the radial metaphysis and diaphysis, the hip, and the total body. Histomorphometric analysis of transiliac bone biopsies at the end of the study period did not show a significant treatment difference in cortical width, trabecular bone volume, or parameters of bone turnover. Similarly, there was no detectable treatment effect on vertebral morphometry, second metacarpal cortical width, grip force, bone pain, or number of new fractures. Regarding safety, risedronate was generally well tolerated, and the incidence of clinical or laboratory adverse experiences was similar among treatment groups. These results suggest that the skeletal effects of oral risedronate are weaker than those that are commonly observed with intravenous pamidronate treatment but still lead to an increase in lumbar spine areal BMD. Future studies should investigate whether oral risedronate is effective in reducing fracture rates in children and adolescents with mild OI type I.<\/jats:p>","DOI":"10.1359\/jbmr.090213","type":"journal-article","created":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T19:12:00Z","timestamp":1236107520000},"page":"1282-1289","source":"Crossref","is-referenced-by-count":108,"title":["Risedronate in the Treatment of Mild Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study"],"prefix":"10.1093","volume":"24","author":[{"given":"Frank","family":"Rauch","sequence":"first","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig F","family":"Munns","sequence":"additional","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Land","sequence":"additional","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira","family":"Cheung","sequence":"additional","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis H","family":"Glorieux","sequence":"additional","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020319595215600_bib1","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"2024020319595215600_bib2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020319595215600_bib3","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"},{"key":"2024020319595215600_bib4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024020319595215600_bib5","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020319595215600_bib6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.bpo.0000176162.78980.ed","article-title":"Impact of alendronate on quality of life in children with osteogenesis imperfecta","volume":"25","author":"Seikaly","year":"2005","journal-title":"J Pediatr Orthop"},{"key":"2024020319595215600_bib7","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: A 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"key":"2024020319595215600_bib8","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1651-2227.1999.tb00993.x","article-title":"Bone mineral content and collagen defects in osteogenesis imperfecta","volume":"88","author":"Lund","year":"1999","journal-title":"Acta Paediatr"},{"key":"2024020319595215600_bib9","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.bone.2005.06.007","article-title":"High and low density in the same bone: A study on children and adolescents with mild osteogenesis imperfecta","volume":"37","author":"Rauch","year":"2005","journal-title":"Bone"},{"key":"2024020319595215600_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1440-1754.2003.00083.x","article-title":"Use of bisphosphonate therapy for osteoporosis in childhood and adolescence","volume":"39","author":"Batch","year":"2003","journal-title":"J Paediatr Child Health"},{"key":"2024020319595215600_bib11","first-page":"77","article-title":"Modern approach to children with osteogenesis imperfecta","volume":"12","author":"Zeitlin","year":"2003","journal-title":"J Pediatr Orthop B"},{"key":"2024020319595215600_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1542\/peds.109.1.45","article-title":"Centers for Disease Control and Prevention 2000 growth charts for the United States: Improvements to the 1977 National Center for Health Statistics version","volume":"109","author":"Ogden","year":"2002","journal-title":"Pediatrics"},{"key":"2024020319595215600_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/00000441-195909000-00030","volume-title":"Radiographic Atlas of Skeletal Development of the Hand and Wrist","author":"Greulich","year":"1959"},{"key":"2024020319595215600_bib14","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bone.2006.04.004","article-title":"Vertebral morphometry in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate treatment","volume":"39","author":"Land","year":"2006","journal-title":"Bone"},{"key":"2024020319595215600_bib15","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1210\/jcem-70-5-1330","article-title":"Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: Correlations with growth parameters","volume":"70","author":"Glastre","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319595215600_bib16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1148\/radiology.179.3.2027984","article-title":"Bone mass in healthy children: Measurement with quantitative DXA","volume":"179","author":"Southard","year":"1991","journal-title":"Radiology"},{"key":"2024020319595215600_bib17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bone.2006.11.020","article-title":"Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta","volume":"40","author":"Rauch","year":"2007","journal-title":"Bone"},{"key":"2024020319595215600_bib18","first-page":"E680","article-title":"Influence of serum Ca concentration on circulating molecular forms of PTH in three species","volume":"251","author":"D'Amour","year":"1986","journal-title":"Am J Physiol"},{"key":"2024020319595215600_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S8756-3282(99)00257-4","article-title":"Normative data for iliac bone histomorphometry in growing children","volume":"26","author":"Glorieux","year":"2000","journal-title":"Bone"},{"key":"2024020319595215600_bib20","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res"},{"key":"2024020319595215600_bib21","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1210\/jc.2002-021371","article-title":"Osteogenesis imperfecta types I, III, and IV: Effect of pamidronate therapy on bone and mineral metabolism","volume":"88","author":"Rauch","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319595215600_bib22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/00003495-200161050-00013","article-title":"Risedronate: A review of its pharmacological properties and clinical use in resorptive bone disease","volume":"61","author":"Dunn","year":"2001","journal-title":"Drugs"},{"key":"2024020319595215600_bib23","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42\u2032446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024020319595215600_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis","volume":"30","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"2024020319595215600_bib25","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study","volume":"15","author":"Reid","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2024020319595215600_bib26","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/(SICI)1097-0185(199712)249:4<458::AID-AR5>3.0.CO;2-N","article-title":"Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: A comparative histomorphometric study on the cancellous bone formed before, during, and after treatment","volume":"249","author":"Pataki","year":"1997","journal-title":"Anat Rec"},{"key":"2024020319595215600_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.090213","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/24\/7\/1282\/56575044\/5650240716.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/24\/7\/1282\/56575044\/5650240716.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:52:15Z","timestamp":1710341535000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/24\/7\/1282-1289\/7599905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,1]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2009,7,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.090213","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,7,1]]},"published":{"date-parts":[[2009,7,1]]}}}